Search results
Showing 136 to 150 of 250 results for carcinoma
Discontinued [GID-TA10811]
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]
Discontinued [GID-TA11240]
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Awaiting development [GID-TA11592] Expected publication date: TBC
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
Discontinued [GID-TA10259]
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued [GID-TA11041]
Palliative photodynamic therapy for advanced oesophageal cancer (IPG206)
Evidence-based recommendations on palliative photodynamic therapy for treating advanced oesophageal cancer. This involves injecting a photosensitising agent into the tumour and using light to activate it and destroy the tumour cells.
View recommendations for IPG206Show all sections
Sections for IPG206
Discontinued [GID-TA10698]
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic
Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]
Discontinued [GID-TA10634]
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)
Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults.
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Discontinued [GID-TA11000]